久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 国产三香港三韩国三级不卡 | 福利片成人午夜在线 | 91pao强力打造免费高清 | 曰批美女免费视频播放 | 男人的天堂在线免费视频 | 久久视频这里只有精品 | 亚洲高清视频在线观看 | 能直接看的一级欧美毛片 | 亚洲精品一区二区久久 | 亚洲人成在线播放网站岛国 | 九九99靖品 | 精品成人毛片一区二区视 | 免费观看性欧美一级 | 日本68xxxxxxxxx老师 | 国产成人精品日本亚洲语音1 | 草草影院在线观看 | 免费视频久久久 | 国产精品伦理久久久久 | 99久久精品免费精品国产 | 在线久久 | 久久99精品视香蕉蕉 | 成人免费一级毛片在线播放视频 | 毛片a级三毛片免费播放 | 在线aaa| 俄罗斯黄色一级片 | 国产福利社区 | 一区二区3区免费视频 | 国产精品色午夜视频免费看 | 99视频在线观看免费 | 国产一级性生活 | 国产精品久久久久久一区二区三区 | 国产成人18黄网站免费 | 国产成人精品在视频 | 99久久香蕉国产线看观香 | 亚洲美女视频一区二区三区 | 亚洲精品视频免费观看 | 鲁老汉精品视频在线观看 | 日本免费一级视频 | 亚洲成人黄色网 | 欧美在线一级毛片视频 | 黄色毛片免费在线观看 |